Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p by Gardner, Richard G. et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/2000/10/69/14 $5.00
The Journal of Cell Biology, Volume 151, Number 1, October 2, 2000 69–82
http://www.jcb.org/cgi/content/full/151/1/69 69
 
Endoplasmic Reticulum Degradation Requires Lumen to Cytosol 
Signaling: Transmembrane Control of Hrd1p by Hrd3p
 
Richard G. Gardner, Gwendolyn M. Swarbrick, Nathan W. Bays, Stephen R. Cronin, Sharon Wilhovsky, 
Linda Seelig, Christine Kim, and Randolph Y. Hampton
 
Division of Biology, University of California at San Diego, La Jolla, California 92093
 
Abstract. 
 
Endoplasmic reticulum (ER)-associated deg-
radation (ERAD) is required for ubiquitin-mediated
destruction of numerous proteins. ERAD occurs by
processes on both sides of the ER membrane, including
lumenal substrate scanning and cytosolic destruction by
the proteasome. The ER resident membrane proteins
Hrd1p and Hrd3p play central roles in ERAD. We
show that these two proteins directly interact through
the Hrd1p transmembrane domain, allowing Hrd1p sta-
bility by Hrd3p-dependent control of the Hrd1p RING-
H2 domain activity. Rigorous reevaluation of Hrd1p to-
pology demonstrated that the Hrd1p RING-H2 domain
is located and functions in the cytosol. An engineered,
completely lumenal, truncated version of Hrd3p func-
tioned normally in both ERAD and Hrd1p stabili-
zation, indicating that the lumenal domain of Hrd3p
 
regulates the cytosolic Hrd1p RING-H2 domain by
signaling through the Hrd1p transmembrane domain.
Additionally, we identiﬁed a lumenal region of Hrd3p
dispensable for regulation of Hrd1p stability, but abso-
lutely required for normal ERAD. Our studies show
that Hrd1p and Hrd3p form a stoichiometric complex
with ERAD determinants in both the lumen and the
 
cytosol. The 
 
HRD
 
 complex engages in lumen to cytosol
communication required for regulation of Hrd1p stabil-
ity and the coordination of ERAD events on both sides
of the ER membrane.
Key words: proteasome • endoplasmic reticulum •
ubiquitin ligase • transmembrane signaling • topology
 
Introduction
 
A significant component of eukaryotic cellular protein
degradation occurs at the ER. ER-associated degradation
 
(ERAD)
 
1
 
 is widely employed in cellular quality control,
resulting in the destruction of numerous misfolded or mu-
tant proteins present in the lumen or at the surface of the
organelle (Ciccarelli et al., 1993; Finger et al., 1993; Ward
et al., 1995; Biederer et al., 1996). ERAD continuously oc-
curs in normal cells to minimize levels of unfolded pro-
teins in the ER lumen (Travers et al., 2000). ERAD is also
used to regulate the steady state levels of specific proteins
in response to physiological cues (Edwards et al., 1983;
Nakanishi et al., 1988; Chun et al., 1990; Hampton and
Rine, 1994; Yeung et al., 1996; Fisher et al., 1997; Zhou et
al., 1998). For instance, production of sterols by the meva-
 
lonate pathway is controlled, in part, by the regulated,
 
ER-associated destruction of hydroxymethylglutaryl-
coenzyme A reductase (HMGR), a key enzyme of the
mevalonate pathway.
Genes involved in ERAD have been identified by sev-
eral genetic analyses in yeast (Hampton et al., 1996a;
Hiller et al., 1996; Knop et al., 1996; Hampton and Bhakta,
1997; Bordallo et al., 1998; Plemper et al., 1999). These
studies indicate that the ER-associated ubiquitin-conju-
gating enzyme Ubc7p is centrally involved in the degrada-
 
tion of ER substrates (Biederer
 
 
 
et al., 1996; Hiller et al.,
1996; Hampton and Bhakta, 1997; Wilhovsky et al. 2000;
and our unpublished results), sometimes in conjunction
 
with other ubiquitin-conjugating enzymes (Biederer
 
 
 
et
 
al., 1996; Friedlander et al., 2000; and our unpublished
 
results). These studies also revealed two previously
unknown membrane proteins, Hrd1p (also isolated as
Der3p) and Hrd3p, required for the ER degradation of
numerous proteins (Hampton
 
 
 
et al., 1996a; Bordallo et al.,
1998; Plemper et al., 1999). Unlike Ubc7p, the functions of
Hrd1p and Hrd3p are not as clear. Our recent work dem-
onstrates that Hrd1p provides the core ubiquitin ligase
(E3) activity in ERAD (our unpublished results), recruit-
ing Ubc7p for substrate ubiquitination. However, the in-
terplay and specific actions of Hrd1p/Hrd3p are poorly de-
fined in current models of ERAD.
A key, but poorly understood feature of ERAD is the
coordination of molecular processes on separate sides of
the ER membrane. The degradation process begins in the
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interior of the ER, where ERAD substrates partially or
completely present in the lumen are recognized for degra-
dation by an unknown mechanism. Many proteins re-
quired for ERAD have critical determinants located in
the lumen (Hampton et al., 1996a; Bordallo et al., 1998;
Plemper et al., 1999; Saito et al., 1999; Zhou and Schek-
man, 1999). However, ubiquitination and degradation of
ERAD substrates occur on the cytosolic face of the ER by
the action of ER-associated ubiquitin-conjugating en-
zymes and the 26S proteasome (Hampton et al., 1996a;
Hiller et al., 1996; Hampton and Bhakta, 1997; Plemper et
al., 1998). How these membrane-separated events are co-
ordinated is not clear. In particular, it is unknown if Hrd1p
and Hrd3p function to allow communication across the
ER membrane.
Hrd3p is an ER resident glycoprotein with a single
membrane span near the COOH terminus and a large
NH
 
2
 
-terminal region in the lumen of the ER (Hampton et
al., 1996a; Saito
 
 
 
et al., 1999; Plemper
 
 
 
et al., 1999). Hrd3p
has widely conserved sequence motifs and full-length
orthologues in a variety of species (Hampton
 
 
 
et al., 1996a;
Donoviel et al., 1998), including the 
 
Caenorhabditis ele-
gans
 
 SEL-1 protein, which may participate in membrane
protein degradation (Grant and Greenwald, 1997). How-
ever, the exact role of Hrd3p in ER degradation has yet to
be elucidated.
Hrd1p is also an ER-associated protein with two distinct
domains: an NH
 
2
 
-terminal, hydrophobic region with mul-
tiple predicted transmembrane spans and a COOH-termi-
nal, hydrophilic region containing a RING-H2 motif re-
quired for the function of Hrd1p in ER degradation
(Hampton
 
 
 
et al., 1996a; Bordallo
 
 
 
et al., 1998). The Hrd1p
RING-H2 motif is conserved in a group of ubiquitin li-
gases or E3 proteins, including Ubr1p (Xie and Var-
shavsky, 1999), Hrt1p/Rbx1p (Ohta et al., 1999a; Seol et
al., 1999; Skowyra
 
 
 
et al., 1999), Apc11p (Peters, 1999), and
c-Cbl (Joazeiro
 
 
 
et al., 1999). In fact, we have recently dem-
onstrated that Hrd1p is a ubiquitin ligase, catalyzing the
transfer of ubiquitin from Ubc7p to ERAD substrates by
the activity of its RING-H2 motif, which is required for a
direct in vivo physical interaction between Hrd1p and
Ubc7p (our unpublished results). Unlike other family
members, the Hrd1p RING-H2 domain is anchored to the
ER membrane by an NH
 
2
 
-terminal, multimembrane span-
ning domain. Although the Hrd1p NH
 
2
 
-terminal trans-
membrane domain contains conserved sequences, no func-
tion has been suggested for this anchor.
In this paper, we have performed an extensive study of
the functional interplay between Hrd1p and Hrd3p. From
these studies, we have demonstrated for the first time a di-
rect physical interaction between the two proteins, defined
domain-specific functions for each protein, ascertained the
correct topology of Hrd1p, demonstrated transmembrane
communication between Hrd1p and Hrd3p, and evaluated
the importance of the stoichiometry of the Hrd1p–Hrd3p
complex. Importantly, we have clearly shown that the
Hrd1p transmembrane domain alone mediates the inter-
action between Hrd1p and Hrd3p. This interaction regu-
lates the activity of the Hrd1p cytosolic RING-H2 domain
to allow ERAD by preventing Hrd1p degradation. Hrd3p-
mediated regulation of the cytosolic Hrd1p RING-H2 do-
main occurs across the ER membrane, as a completely lu-
 
menal version of Hrd3p allowed ERAD through normal
regulation of Hrd1p stability. These studies further dem-
onstrated that the lumenal functions of Hrd3p include
both transmembrane regulation of Hrd1p RING-H2 do-
main activity and as yet undefined aspects of ERAD sepa-
rate from control of Hrd1p stability.
 
Materials and Methods
 
Materials and Reagents
 
Rabbit anti-hemagglutinin (HA) polyclonal antiserum was obtained from
Babco. Rabbit polyclonal anti–green fluorescent protein (GFP) antiserum
was obtained from Dr. Suresh Subramani (University of California at San
Diego). Rabbit polyclonal antiserum to the COOH-terminal residues 348–
551 of Hrd1p or the NH
 
2
 
-terminal residues 220–417 of Hrd3p was made in
collaboration with Scantibodies, Inc. All other materials and reagents
were obtained from previously described sources (Gardner et al., 1998).
 
Plasmids and DNA Methods
 
All DNA manipulations were performed as described (Gardner et al.,
1998), using the reagents described therein. For PCR amplifications,
primer sequences will be provided upon request.
Plasmids expressing epitope-tagged versions of the 
 
HRD
 
 genes were
constructed as follows. pRH1196 (YIp/
 
TRPI
 
) expressed Hrd1p with a tri-
ple HA epitope sequence fused in frame to the immediate COOH termi-
nus. Integration at the 
 
HRD1 
 
genomic locus resulted in expression of only
3HA-Hrd1p. The triple HA epitope sequence was fused to the 
 
HRD1
 
 se-
quence through the splicing by overlap extension (SOEing) PCR tech-
nique (Horton et al., 1989). The 
 
3HA-HRD1
 
 gene complemented an
 
hrd1
 
D
 
 mutation when integrated as a single copy behind the native 
 
HRD1
 
promoter. pRH1263 contained a triple HA epitope sequence inserted be-
tween codons 20 and 21 of the 
 
HRD3
 
 sequence cloned from pYS14 (Saito
et al., 1999). Integration of pRH1263 at the 
 
HRD3
 
 genomic locus resulted
in expression of only 3HA-Hrd3p, which complemented an 
 
hrd3
 
D
 
 muta-
tion when expressed from the native promoter. pRH1048 allowed expres-
sion of 3HA-Hrd3p from the glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (
 
TDH3
 
) promoter (Bitter and Egan, 1984). The plasmid was
constructed by subcloning a PCR-generated DNA fragment encoding the
5
 
9
 
 sequence of the 
 
3HA-HRD3
 
 allele between the XhoI and NheI sites in
pRH632 (YIp/
 
LEU2
 
/P
 
TDH3
 
-
 
HRD3
 
), thereby replacing the corresponding
normal 
 
HRD3
 
 sequence.
Plasmids expressing the Hrd1p NH
 
2
 
-terminal transmembrane domain,
called hemi-Hrd1p, were constructed as follows. pRH936 (YIp/
 
TRP1
 
) al-
lowed hemi-Hrd1p expression from the GAPDH promoter. The hemi-
Hrd1p coding region was prepared by PCR amplification of the 5
 
9
 
 end of
 
HRD1
 
 between the 
 
HRD1
 
 start codon and the NcoI site just distal to the
end of the transmembrane domain coding region. The PCR product was
cloned into a 
 
TRP1
 
 variant of pRH98-2 (Hampton et al., 1996b), placing
 
hemi-HRD1
 
 behind the GAPDH promoter, yielding pRH936. pRH986
(YIp/
 
TRP1
 
), which allowed expression of 1myc-hemi-Hrd1p from the
GAPDH promoter, was prepared from pRH936 by addition of a PCR-
generated DNA fragment encoding a single myc epitope sequence (EQK-
LISEEDL) to the 3
 
9
 
 end of 
 
hemi-HRD1
 
. The DNA fragment replaced the
sequence between the NsiI and KpnI sites in pRH936. pRH1297 (YIp/
 
TRP1
 
) allowed expression of hemi-Hrd1p-GFP from the GAPDH pro-
moter. hemi-Hrd1p-GFP contained a replacement of the Hrd1p COOH-
terminal domain with the autofluorescent GFP protein. The GFP fusion
sequence was created by SOEing PCR amplification of the GFP coding
sequence from pRH469 (Gardner et al., 1998), and replaced the sequence
between the NsiI and KpnI sites in pRH936.
Plasmids expressing the isolated COOH-terminal RING-H2 domain of
Hrd1p, termed RING-Hrd1p, were constructed as follows. The plasmid
pRH730 (YIp/
 
TRP1
 
), which contained 
 
3HA-HRD1
 
 behind the GAPDH
promoter, was digested with NcoI, the ends were filled in, and the result-
ing plasmid was religated to form pRH1227. The P
 
TDH3
 
-RING-HRD1 al-
lele was subcloned into pRH1153 (YIp/
 
LEU2
 
), which contained the nor-
mal 
 
HRD1
 
 gene, to yield pRH1303. The GFP coding sequence was fused
to the 5
 
9
 
 end of 
 
HRD1
 
 through the PCR SOEing method, and the result-
ing plasmid was named pRH684 (YIp/
 
TRP1
 
). The GFP fusion portion of
this construct was subcloned into the 
 
RING-HRD1
 
 plasmid to yield
pRH1231 (YIp/
 
TRP1/RING-HRD1-GFP
 
). 
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The C399S Hrd1p point mutation was generated by PCR SOEing and
introduced into the 
 
HRD1
 
 coding region of the plasmids described above
to yield pRH1245 (YIp/
 
TRPI/C399S-HRD1
 
) and pRH1314 (YIp/
 
TRPI/
C399S-RING-HRD1
 
).
The 
 
HRD3
 
 truncation plasmids were constructed as follows. Deletion
of codons 768–833 was accomplished by generating a DNA fragment con-
taining a stop codon and XbaI site placed after codon 767 in the 
 
HRD3
 
coding region by PCR SOEing and introducing the DNA into pRH508.
The subsequent plasmid was digested with XbaI to remove the DNA en-
coding the transmembrane domain and cytosolic extension, and the result-
ing plasmid was named pRH1244. Deletion of codons 393–833 was accom-
plished by digesting pRH508 with NdeI and religating the vector fragment
to yield the plasmid pRH1219. Deletion of codons 24–356 was accom-
plished by generating a DNA fragment containing an SalI site placed after
codon 24 in the 
 
HRD3
 
 coding region by PCR SOEing and introducing the
DNA into pRH508 (YIp/
 
LEU2
 
). The subsequent plasmid was digested
with SalI to remove the intervening DNA, and the resulting plasmid was
named pRH1242. The various 
 
HRD3
 
 truncation alleles, 
 
HRD3
 
1–767
 
,
 
HRD3
 
1–390
 
, and 
 
HRD3
 
357–833
 
, were cloned by the 
 
TDH3
 
 promoter in
pRH632 to yield pRH1249, pRH1252, and pRH1248, respectively.
 
Strains and Transformations
 
Yeast and bacteria were cultured as described (Gardner et al., 1998). Har-
vest, lysis, and transformation protocols were all standard and identical to
those described (Gardner et al., 1998).
All yeast strains were derived from the same genetic background used
in all our previous work (Hampton and Rine, 1994; Hampton et al.,
1996b). The parent strain from which every subsequent strain was derived
had the following genotype: 
 
his3D200 lys2-801 ade2-101 ura3-52 met2
hmg1::LYS2 hmg2::HIS3
 
. The subsequent parent strains used for each ap-
propriate experiment had the additional following genotypes and pheno-
types: RHY853 (
 
ura3-52::HMG2cd:: hmg2GFP trp1::hisG leu2
 
D
 
) ex-
pressed Hmg2p-GFP and the catalytic domain of Hmg2p as the sole
source of Hmg2p; RHY1383 (
 
ura3-52::1MYCHMG2:: hmg2GFP trp1::
hisG leu2
 
D
 
) expressed normal, mevalonate pathway–regulated 1myc-
Hmg2p and Hmg2p-GFP; RHY1886 (
 
HMG2
 
) expressed native Hmg2p;
and RHY1914 (
 
HMG2 ura3-52::1MYC-HMG2
 
) expressed normal, meva-
lonate pathway–regulated 1myc-Hmg2p and native Hmg2p.
 
Flow Cytometry
 
Flow cytometric analyses were performed as described (Gardner et al.,
1998). Living cells were analyzed by flow microfluorimetry using a FACS-
Calibur™ (Becton Dickinson) flow microfluorimeter with settings for flu-
orescein-labeled antibody analysis. Histograms were produced from
10,000 individual, log-phase cells.
 
Cycloheximide Chase Degradation Assay
 
Degradation of expressed, epitope-tagged proteins was evaluated by
treatment of log phase strains with cycloheximide as described (Gardner
et al., 1998). In brief, log phase cells were treated with 50 
 
m
 
g/ml cyclohex-
imide to halt protein synthesis, and then lysed and immunoblotted after
various incubation times to evaluate degradation as described (Gardner et
al., 1998). myc-tagged or HA-tagged proteins were detected using the
9E10 or 12CA5 mAbs as described (Gardner et al., 1998).
 
In Vivo Cross-Linking
 
The in vivo cross-linking assay was modified from the in vitro assay de-
scribed (Marcusson et al., 1994). Cells expressing the appropriate epitope-
tagged proteins were grown to log phase (OD
 
600
 
 5 
 
1.0) in 30 ml minimal
medium, harvested by centrifugation, and resuspended in XL buffer (Mar-
cusson et al., 1994) to a density of 6.0 OD
 
600
 
 units. Zymolase was added
(final concentration 50 
 
m
 
g/ml) and dithiobis(succinimidyl-propionate)
(DSP) was added in varying concentrations up to 400 
 
m
 
g/ml. Cells were in-
cubated for 30 min at 30
 
8
 
C. Spheroplasts were harvested by centrifugation
and lysed by resuspension in 300 
 
m
 
l SUME (Hampton and Bhakta, 1997),
plus the detergents deoxycholate (0.5%) and Triton X-100 (1%), which
were in addition to SDS (1%), and 20 
 
m
 
M hydroxylamine to quench the
cross-linking reaction. Supernatants were clarified by centrifugation for 15
min. Supernatants were added to 1 ml immunoprecipitation buffer (IP
buffer) (Hampton and Bhakta, 1997), containing 20–30 
 
m
 
l of the appropri-
ate antisera. Samples were incubated for 16 h at 4
 
8
 
C. Protein A–sepharose
CL-4B beads (100 
 
m
 
l of a 10% wt/vol solution) were added, and the sam-
ples were incubated for 2 h. Beads were harvested by centrifugation and
washed once with IP buffer and once with wash buffer (Hampton and
Bhakta, 1997). Proteins were removed from the beads by addition of 50 
 
m
 
l
2
 
3
 
 USB (Hampton and Bhakta, 1997) and incubation at 55
 
8
 
C for 10 min.
Immunoblotting of precipitated proteins was performed as described
(Gardner et al., 1998). In brief, separate 5- and 35-
 
m
 
l volumes of each pre-
cipitated sample were resolved on 8% SDS-PAGE gels and transferred to
nitrocellulose. The 12CA5 anti-HA antibody was used to detect HA-
tagged proteins, and a polyclonal anti-GFP antisera was used to detect
GFP fusion proteins.
 
Native Coimmunoprecipitation
 
The native immunoprecipitation was adapted from Stack et al. (1993).
Log phase yeast cells (0.75 OD
 
600
 
 units) were harvested by centrifugation
and washed once with distilled water. Cells were resuspended in 0.5 ml zy-
molyase buffer (Marcusson et al., 1994). Zymolase (10 
 
m
 
g) was added to
the cells, which were then incubated for 45 min at 30
 
8
 
C. Cells were washed
once with 0.5 ml of ice-cold IP buffer minus detergent, then resuspended
in 1 ml IP buffer. The resuspended cells were lysed by incubation on ice
for 5 min. The supernatant was clarified by centrifugation for 5 min at 4
 
8
 
C,
and again by centrifugation for 30 min at 4
 
8
 
C. For evaluation of total ly-
sate protein, 20 
 
m
 
l of the final supernatant was removed and added to 20
 
m
 
l of 2
 
3
 
 USB. 7 
 
m
 
l rabbit anti-HA antisera was added to the remaining ly-
sate to immunoprecipitate HA-tagged proteins, and the mixture was incu-
bated overnight at 4
 
8
 
C. Protein A–sepharose CL-4B bead suspension (100
 
m
 
l of a 10% wt/vol solution) was added to the mixture, which was then in-
cubated for 2 h at 4
 
8
 
C. Beads were harvested by centrifugation and
washed twice with IP buffer. Proteins were removed from the beads by
addition of 40 
 
m
 
l 2
 
3
 
 USB and incubation at 55
 
8
 
C for 10 min. Immunoblot-
ting of HA-tagged proteins (5 
 
m
 
l of sample) or coprecipitated myc-tagged
proteins (20 
 
m
 
l of sample) was performed with the 12CA5 or 9E10 mAbs,
respectively.
 
Protease Protection Assay
 
Microsomes were prepared as described previously (Marcusson et al.,
1994). Increasing amounts of protease were added to isolated microsomes,
which were incubated on ice for 30 min. Reactions were stopped, and pro-
teins were denatured by addition of an equal volume of 2
 
3
 
 USB contain-
ing PMSF, followed by incubation at 65
 
8
 
C for 15 min. Samples were re-
solved by SDS-PAGE and immunoblotted with the appropriate antisera
to assess levels of each protein.
 
Results
 
Hrd3p Interacted with the Hrd1p
Transmembrane Domain
 
Previous studies indicated that Hrd1p and Hrd3p func-
tioned in the same ER-associated degradation pathway
and showed genetic interactions (Hampton et al., 1996a;
Bordallo et al., 1998; Plemper et al., 1999; Wilhovsky et al.,
2000). Therefore, we first examined if Hrd1p and Hrd3p
physically interacted by chemical cross-linking and native
immunoprecipitation assays.
Physical interactions between Hrd1p and Hrd3p were
determined using an in vivo cross-linking assay modified
from a procedure for cell lysates (Marcusson et al., 1994).
The strains used for the cross-linking assays expressed
fully functional, triple HA epitope–tagged versions of
Hrd1p and/or Hrd3p from their native promoters. Each
modified protein completely complemented
 
 
 
the respective
null alleles for ERAD when expressed in single copy from
their native promoters (data not shown). When lysates
were derived from cells treated with increasing amounts of
cross-linker and Hrd1p was immunoprecipitated using
Hrd1p-specific antisera, Hrd3p coimmunoprecipitated in a
cross-linker concentration–dependent fashion (Fig. 1 a,
top left). In the absence of cellular Hrd1p, no cross-linker– 
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dependent Hrd3p coimmunoprecipitation was observed
(Fig. 1 a, top right). The small amount of Hrd3p that coim-
munoprecipitated with Hrd1p in the absence of cross-
linker was roughly equivalent to that seen in the absence
of Hrd1p, indicating that this amount was nonspecific.
We evaluated the importance of each Hrd1p domain in
the Hrd3p interaction by testing Hrd1p truncation mu-
tants and fusion proteins. We first tested if the Hrd1p
NH
 
2
 
-terminal transmembrane domain, defined by resi-
dues 1–233, cross-linked with Hrd3p. In these and the fol-
lowing genetic studies, we refer to versions of Hrd1p that
contained only the NH
 
2
 
-terminal transmembrane domain
as hemi-Hrd1p because this domain is roughly one half the
size of normal Hrd1p (Fig. 1 b). The Hrd1p/Hrd3p cross-
linking experiment was repeated in a strain coexpressing
hemi-Hrd1p-GFP, a fusion protein consisting of the NH
 
2
 
-
terminal domain of Hrd1p fused to GFP, and 3HA-Hrd3p.
Immunoprecipitation of hemi-Hrd1p-GFP with anti-GFP
antisera resulted in coimmunoprecipitation of Hrd3p in a
cross-linker–dependent manner (Fig. 1 c, top left). When
 
the same experiment was performed on cells that did
not express hemi-Hrd1p-GFP, no cross-linker–dependent
Hrd3p coimmunoprecipitation was observed (Fig. 1 c, top
right).
We also tested if the Hrd1p COOH-terminal RING-H2
domain cross-linked with Hrd3p when expressed as an iso-
lated protein encompassing residues 224–551 of Hrd1p.
We refer to the 327-residue COOH-terminal domain as
RING-Hrd1p because it contains the RING-H2 motif
(Fig. 1 b). When the same cross-linking assay was per-
formed in strains coexpressing 3HA-Hrd3p and RING-
Hrd1p-GFP, which contained GFP fused in frame to the
extreme COOH terminus of RING-Hrd1p, no cross-
linker–dependent Hrd3p coimmunoprecipitation was ob-
served (Fig. 1 c, top middle). Similarly, the isolated RING-
Hrd1p without GFP also did not cross-link to Hrd3p (data
not shown). Thus, the isolated COOH-terminal RING-H2
domain did not appear to interact with Hrd3p, despite it
having a dominant negative ERAD phenotype and ER
membrane localization (see below).
Figure 1. Hrd1p and Hrd3p interacted via the Hrd1p NH2-terminal transmembrane domain. (a) Hrd3p cross-linked to Hrd1p. Log
phase cells expressing the indicated 3HA epitope–tagged proteins were treated with the indicated concentrations of DSP, lysed, and im-
munoprecipitated with anti-Hrd1p antisera. Precipitated proteins were next immunoblotted with an anti-HA mAb to detect coimmuno-
precipitated 3HA-Hrd3p (top) or with an anti-Hrd1p polyclonal antisera to verify equal amounts of immunoprecipitated Hrd1p (bot-
tom). (b) Cartoon depicting Hrd1p topology. Top row, linear representation of Hrd1p domains. The start and end of each domain are
indicated by the number of the corresponding amino acid residue below. Bottom row, cartoon representations of the various Hrd1p
constructs including wt-Hrd1p, only the Hrd1p transmembrane domain (hemi-Hrd1p), and only the COOH-terminal RING-H2 domain
(termed RING-Hrd1p). (c) Hrd3p cross-linked to hemi-Hrd1p-GFP, but not RING-Hrd1p-GFP. Cells coexpressing 3HA-Hrd3p and
the indicated Hrd1p-GFP fusion were subject to the cross-linking assay using anti-GFP antisera to immunoprecipitate the Hrd1p-GFP
fusions from the lysates. Precipitated proteins were immunoblotted with an anti-HA mAb to detect coimmunoprecipitated 3HA-Hrd3p
(top), or with an anti-GFP mAb to detect immunoprecipitated Hrd1p-GFP fusions (bottom). (d) hemi-Hrd1p expression inhibited
Hrd3p cross-linking Hrd1p. The same cross-linking assay in panel a was performed with cells expressing 3HA-Hrd3p with or without
the PTDH3-hemi-HRD1 allele. To compensate for lower Hrd1p in the hemi-Hrd1p cells (see Fig. 4 a), four times less lysate was used in
the control lanes so that all lanes had identical amounts of immunoprecipitated Hrd1p. (e) Native coimmunoprecipitation of hemi-
Hrd1p with Hrd3p. Cells expressing either 1myc-hemi-Hrd1p, 3HA-Hrd3p, or both proteins were lysed under nondenaturing condi-
tions and immunoprecipitated with anti-HA polyclonal antisera. Immunoprecipitates were immunoblotted with the appropriate mAb
to detect coimmunoprecipitated 1myc-hemi-Hrd1p (bottom) or immunoprecipitated 3HA-Hrd3p (top). (f) hemi-Hrd1p coimmunopre-
cipitated with Hrd3p only when expressed in the same cell. Same experiment as in panel d, except 1myc-hemi-Hrd1p and 3HA-Hrd3p
were expressed either in the same cell or in separate cells (sep). Cells expressing each protein individually were mixed in equal quanti-
ties and lysed. Cells expressing both proteins were mixed with an equal number of empty cells to ensure an equal protein load and lysed
(cartoon). Each lysate (right) was immunoblotted with an anti-myc mAb to detect total 1myc-hemi-Hrd1p (bottom) or with an anti-HA
mAb to detect total Hrd3p (top). 
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These mapping experiments indicated that the Hrd1p
NH2-terminal transmembrane domain was necessary and
sufficient for the Hrd1p–Hrd3p interaction. Accordingly,
we tested if overexpression of hemi-Hrd1p could compete
with native Hrd1p for Hrd3p cross-linking. When hemi-
Hrd1p was coexpressed from the strong TDH3 promoter
(also known as the GAPDH promoter; Bitter and Egan,
1984) in the strain used to examine the Hrd1p–Hrd3p in-
teraction, Hrd3p cross-linking to Hrd1p was eliminated
(Fig. 1 d, compare top panels). It is important to point out
that hemi-Hrd1p expression resulted in decreased Hrd1p
levels in the cell (see below, Fig. 3). To account for this,
the same amount of total Hrd1p immunoprecipitated was
loaded in each lane so that the amount of cross-linked
Hrd3p could be directly compared.
The interaction between Hrd3p and hemi-Hrd1p was
further tested with a native coimmunoprecipitation assay,
in which membrane proteins were solubilized under non-
denaturing conditions to preserve protein–protein associa-
tions (Stack et al., 1993). We used a myc epitope–tagged
version of hemi-Hrd1p to test if the NH2-terminal domain
could, by itself, interact with Hrd3p. 1myc-hemi-Hrd1p,
containing a single, myc epitope sequence placed in frame
after residue 231 of hemi-Hrd1p, was coexpressed in cells
that also expressed 3HA-Hrd3p. When 3HA-Hrd3p was
immunoprecipitated using anti-HA antibodies, 1myc-
hemi-Hrd1p was coimmunoprecipitated (Fig. 1 e). In con-
trast, hemi-Hrd1p coimmunoprecipitation was not ob-
served when untagged Hrd3p was coexpressed in the cells
(Fig. 1 e). Coimmunoprecipitation was not the result of as-
sociation between the two proteins through the action of
the detergent lysis buffers, as 1myc-hemi-Hrd1p coimmu-
noprecipitation only occurred when coexpressed in the
same cells as 3HA-Hrd3p (Fig. 1 f).
Together, these experiments demonstrated that Hrd1p
physically interacted with Hrd3p through the Hrd1p NH2-
terminal transmembrane domain. The COOH-terminal,
RING-H2 domain was dispensable for the interaction and
did not appear to be able to interact with Hrd3p when ex-
pressed as an isolated protein.
Figure 2. Dominant negative truncation mutants of Hrd1p. (a) hemi-Hrd1p expression stabilized Hmg2p-GFP similar to a RING-H2
deletion mutant of Hrd1p. Flow cytometry of log phase strains expressing Hmg2p-GFP (wt) or coexpressing hemi-Hrd1p or the RING-
H2 motif deletion mutant of Hrd1p as indicated. The stabilizing effect of the hemi-HRD1 allele or the DH2-hrd1 allele was seen by the
rightward shift in the fluorescence histogram compared with the wild-type strain. (b) Hrd3p overexpression reversed the hemi-HRD1
phenotype for 1myc-Hmg2p degradation. Isogenic strains expressing hemi-Hrd1p only (empty vector) or those coexpressing either the
PTDH3-HRD3  or the PTDH3-HRD1 allele were assayed for 1myc-Hmg2p degradation by cycloheximide-chase assay, along with an
isogenic wild-type strain (wt) without hemi-Hrd1p. Cell lysates were prepared at the indicated times after cycloheximide addition and
immunoblotted using the 9E10 anti-myc mAb. (c) Hrd3p overexpression reversed the PTDH3-hemi-HRD1 phenotype for Hmg2p-GFP
degradation. Flow cytometric analysis of strains expressing Hmg2p-GFP and the indicated alleles was performed as above in panel a.
(d) RING-Hrd1p expression stabilized Hmg2p-GFP. Isogenic strains expressing Hmg2p-GFP and coexpressing either RING-Hrd1p
(RING-HRD1), C399S-RING-Hrd1p (C399S-RING-HRD1), or full-length C399S-Hrd1p (C399S-hrd1) were analyzed by flow cytome-
try as in panel a. (e) Hrd3p overexpression did not suppress the RING-HRD1 phenotype for 1myc-Hmg2p degradation. Isogenic strains
expressing RING-Hrd1p only (empty vector) or those coexpressing either the PTDH3-HRD3 allele or the PTDH3-HRD1 allele, were as-
sayed for 1myc-Hmg2p degradation by cycloheximide chase assay along with a wild-type strain not expressing RING-Hrd1p. Cell ly-
sates were prepared at the indicated times after cycloheximide addition and immunoblotted using the 9E10 anti-myc mAb. (f) Hrd3p
overexpression did not reverse the PTDH3-RING-HRD1 phenotype for Hmg2p-GFP degradation. Flow cytometry of strains expressing
Hmg2p-GFP and the indicated alleles was performed as in panel a.The Journal of Cell Biology, Volume 151, 2000 74
Phenotypes and Suppression of HRD1
Truncation Alleles
It has been shown that expression of a full-length, mutant
version of Hrd1p, C399S-Hrd1p, results in a dominant
negative block in ERAD (Bordallo and Wolf, 1999),
which is suppressed by increased Hrd3p expression (Plem-
per et al., 1999). We tested each half of Hrd1p for domi-
nant negative ERAD phenotypes and suppression by
Hrd3p overexpression.
Overproduction of hemi-Hrd1p in wild-type strains
strongly stabilized the ERAD substrate Hmg2p-GFP, re-
sulting in increased cellular fluorescence in hemi-HRD1
cells compared with control cells as measured by flow cy-
tometry (Fig. 2 a). The hemi-HRD1 stabilizing effect was
identical to the effect of a previously reported dominant
negative stabilizing HRD1 allele encoding a protein with
the RING-H2 motif deleted (Bordallo et al., 1998) (Fig. 2
a). Expression of hemi-Hrd1p also stabilized the regulated
ERAD substrate 1myc-Hmg2p (Fig. 2 b) and the constitu-
tive ERAD substrate 6myc-Hmg2p (data not shown), as
measured by the direct assay of each protein’s stability.
Surprisingly, overexpression of the isolated Hrd1p
COOH-terminal domain, RING-Hrd1p, also had a domi-
nant negative stabilizing phenotype on Hmg2p-GFP deg-
radation (Fig. 2 d). The stabilizing effect of RING-Hrd1p
expression required an intact RING-H2 motif, as a point
mutation in a critical cysteine within the motif, analogous
to C399S in full-length Hrd1p, strongly suppressed the sta-
bilizing effect of the RING-HRD1 allele (Fig. 2 d). This
was in direct contrast to the stabilizing effect of the C399S
point mutation in full-length Hrd1p (Fig. 2 d). The dimin-
ished stabilizing effect of C399S-RING-Hrd1p occurred
despite its increased levels compared with RING-Hrd1p
(see below). The dominant phenotype of the RING-
HRD1 allele and its reversal by the C399S point mutation
were also observed for degradation of 1myc-Hmg2p and
6myc-Hmg2p (data not shown).
The full-length C399S-Hrd1p dominant negative pheno-
type is suppressed by Hrd3p overexpression (Bordallo and
Wolf, 1999). Therefore, we evaluated the effect of Hrd3p
overexpression on the dominant stabilizing phenotype of
each Hrd1p truncation mutant. The dominant negative
phenotype of the hemi-HRD1 allele was reversed by in-
creased expression of Hrd3p from the TDH3 promoter, as
measured by cycloheximide chase assay of 1myc-Hmg2p
degradation (Fig. 2 b), or Hmg2p-GFP steady state fluo-
rescence (Fig. 2 c). Suppression by HRD3 was complete,
since the fluorescence histogram of the suppressed cells
could be superimposed on that of the wild-type strain (Fig.
2 c). Importantly, neither the stability nor the steady state
levels of hemi-Hrd1p were affected by increased Hrd3p
expression (data not shown). Increased Hrd1p expression
from the TDH3 promoter also reversed the hemi-HRD1
phenotype as expected (Fig. 2, b and c).
Conversely, the dominant negative stabilizing pheno-
type of RING-Hrd1p was not suppressed by increased
Hrd3p expression. The same expression levels of Hrd3p
had no effect on the RING-HRD1–dependent stabiliza-
tion of 1myc-Hmg2p or Hmg2p-GFP (Fig. 2, e and f, re-
spectively). The lack of suppression was not due to an in-
ability of the RING-HRD1 effect to be suppressed, since
increased Hrd1p expression did completely reverse the
stabilizing effect of the RING-HRD1 allele (Fig. 2, e and
f). Thus, although RING-Hrd1p expression inhibited
ERAD, the stabilizing effect was not through Hrd3p se-
questration or inhibition, as would be expected by its lack
Figure 3. Characteristics of Hrd1p sta-
bility and degradation. (a) hemi-Hrd1p
destabilized Hrd1p by Hrd3p seques-
tration. Stability of 3HA-Hrd1p was as-
sessed by cycloheximide chase assay in
isogenic strains with either the hrd3D
allele, the PTDH3-hemi-HRD1 allele, or
both alleles. Lysates were prepared at
the indicated times after cycloheximide
addition and immunoblotted for the
levels of 3HA-Hrd1p using an anti-HA
mAb. (b) The degradation of full-
length Hrd1p was programmed by the
COOH-terminal RING-H2 domain.
Degradation of Hrd1p, C399S-Hrd1p,
RING-Hrd1p, C399S-RING-Hrd1p, or
hemi-Hrd1p was assessed in otherwise
isogenic strains with wild-type (wt),
hrd3D, or ubc7D alleles by cyclohexim-
ide chase assay. The presence of the
C399S mutation in the degradation
substrate is indicated over the appro-
priate blot. Lysates were prepared at
the indicated times after cycloheximide
addition and immunoblotted for the
levels of 3HA-Hrd1p and 3HA-RING-
Hrd1p using an anti-HA mAb or for
the levels of 1myc-hemi-hrd1p using
the 9E10 anti-myc mAb.Gardner et al. Transmembrane Control of Hrd1p by Hrd3p 75
of interaction with Hrd3p as shown above in the cross-
linking studies.
The Hrd1p Transmembrane Region Mediated
Hrd3p-dependent Stabilization of Hrd1p
One function of Hrd3p in ERAD is regulation of Hrd1p
stability. In the absence of Hrd3p, the stability of Hrd1p is
greatly reduced (Plemper et al., 1999). We evaluated the
role of the Hrd1p NH2-terminal transmembrane domain
in this action of Hrd3p. Expression of hemi-Hrd1p in a
wild-type HRD3 strain mimicked the phenotype of the
hrd3D allele, resulting in a similar decrease in the half-life
and stability of Hrd1p (Fig. 3 a). Hrd1p was restabilized in
this strain by increasing the expression of Hrd3p from the
TDH3 promoter (Fig. 3 a). Thus, in this molecular readout
of Hrd3p function, the isolated Hrd1p transmembrane do-
main sequestered Hrd3p and removed its stabilizing influ-
ence on endogenous Hrd1p.
The two domains of intact Hrd1p had distinct roles in
Hrd3p-dependent regulation of Hrd1p stability. Hrd1p
degradation was mediated by the COOH-terminal RING-
H2 domain, whereas Hrd3p-dependent stabilization was
mediated by the NH2-terminal transmembrane domain. In
an hrd3D strain, Hrd1p degradation was dependent on a
functional UBC7 gene and an intact RING-H2 motif. Loss
of UBC7 function by introduction of a ubc7D allele com-
pletely stabilized Hrd1p (Fig. 3 b), as did introduction of
the C399S mutation (Fig. 3 b). This was consistent with the
previous analysis of Hrd1p degradation in the absence of
HRD3 (Plemper et al., 1999). This was also consistent with
the ubiquitin ligase activity of the Hrd1p RING-H2 do-
main (our unpublished results), and demonstrated the es-
sential nature of the Hrd1p RING-H2 motif’s activity in
the degradation of Hrd1p. Degradation of isolated RING-
Hrd1p, which lacks the NH2-terminal transmembrane re-
gion, was similarly dependent on UBC7 and its own func-
tional RING-H2 motif (Fig. 3 b). However, RING-Hrd1p
degradation was completely independent of Hrd3p, occur-
ring with identical kinetics in the absence or presence of
HRD3 (Fig. 3 b). This indicated that the transmembrane
domain was critical for Hrd3p regulation of Hrd1p stabil-
ity. In contrast, hemi-Hrd1p, which encompasses the iso-
lated transmembrane domain, was exceedingly stable re-
gardless of Hrd3p presence (Fig. 3 b).
The Hrd1p COOH-terminal RING-H2 Domain Was 
Located and Functioned in the Cytosol
It has been previously reported that the COOH-terminal
RING-H2 domain is in the lumen of the ER (Bordallo et
al., 1998). However, the homology of this domain with a
class of ubiquitin ligases, and our concurrent studies of the
Hrd1p biochemical function as a ubiquitin ligase (our un-
published results), led us to rigorously reevaluate the
membrane orientation of the Hrd1p RING-H2 domain.
First, we tested the localization of intact Hrd1p and its
truncation mutants by using the GFP fusions described in
the interaction studies above. To aid visibility, all GFP fu-
sions were expressed in strains with the ubc7D allele, since
both the Hrd1p-GFP and the RING-Hrd1p-GFP were
subject to degradation in a wild-type background (data not
shown, and see Fig. 3). When expressed from the TDH3
promoter, both hemi-Hrd1p-GFP and RING-Hrd1p-GFP
demonstrated identical cellular localization of GFP fluo-
rescence (Fig. 4 a). The GFP fluorescence was primarily
localized to a perinuclear band, as observed by 4,6-
diamino-2-phenylindole (DAPI) staining of the nucleus
(data not shown), with some GFP fluorescence localized
to the periphery of the cell. This type of cellular localiza-
tion is common for ER-localized membrane proteins (Par-
lati et al., 1995; Hampton et al., 1996b; Saito et al., 1999).
The cellular localization of either hemi-Hrd1p-GFP or
RING-Hrd1p-GFP was identical to that observed for full-
length Hrd1p-GFP (Fig. 4 a), which has been previously
determined to be ER localized (Bordallo et al., 1998).
C399S-Hrd1p-GFP had identical ER localization as
Hrd1p-GFP, as expected (Fig. 4 a). Furthermore, the cel-
lular localization of each GFP construct was similar to
Hmg2p-GFP (Fig. 4 a), a known ER-localized membrane
protein (Hampton et al., 1996b).
ER membrane localization was expected for the fusions
containing the NH2-terminal transmembrane domain. It
was surprising that RING-Hrd1p-GFP behaved the same
way since there are no predicted transmembrane spans or
signal sequences within this protein, although such local-
ization was consistent with its dominant inhibition of
ERAD. From this, it seemed likely that RING-Hrd1p
would be bound to the outside of the ER membrane.
Therefore, we performed protease protection assays to
test for cytosolic exposure of the RING-Hrd1p protein.
When intact microsomes were isolated from cells express-
ing 3HA-RING-Hrd1p, nearly all of the immunoreactivity
was associated with the pelleted microsomes (Fig. 4 b,
3HA-RING-Hrd1p; Lys). Brief trypsin treatment at sev-
eral concentrations of protease completely removed the
HA immunoreactivity without need for added detergent
(.2 and .5). The loss of epitope immunoreactivity was iden-
tical to that of 1myc-Hmg2p (Fig. 4 b), which has a myc
epitope sequence placed in the large COOH-terminal, cy-
tosolic region (Hampton and Bhakta, 1997). In contrast,
the immunoreactivity of the completely lumenal Kar2p
was unaffected in the absence of detergent (Fig. 4 b),
whereas 3HA-Hrd3p showed a small shift in molecular
weight (Fig. 4 b), consistent with removal of its small, cyto-
plasmic COOH-terminal region (Plemper et al., 1999;
Saito et al., 1999). All protected proteins were rendered
completely trypsin sensitive by pretreatment of the mi-
crosomes with detergent (Fig. 4 b, .5X).
The Hrd1p COOH-terminal RING-H2 domain was as-
sociated with the ER and accessible from the cytosolic
face of the ER membrane when expressed as an isolated
protein. However, it has been reported that this domain in
full-length Hrd1p was exclusively on the lumenal side of
the ER membrane (Bordallo et al., 1998). Therefore, we
also evaluated the protease sensitivity of the same region
when part of intact Hrd1p by using 3HA-Hrd1p, which
contains the epitope tag at the extreme COOH terminus
and completely complements an hrd1D allele for ER deg-
radation. In an identical protease protection experiment,
the HA immunoreactivity for the COOH-terminal tagged,
full-length 3HA-Hrd1p was also completely destroyed by
trypsin addition in the absence of any added detergent
(Fig. 4 b), exactly like the cytosolic tag on Hmg2p and in
striking contrast to Hrd3p or Kar2p. No accumulation ofThe Journal of Cell Biology, Volume 151, 2000 76
Figure 4. Orientation of Hrd1p proteins and complementation of a hrd1D allele by expression of both the RING-HRD1 and hemi-
HRD1 alleles. (a) RING-Hrd1p-GFP was localized to the ER. Fluorescence microscopy was performed on otherwise isogenic ubc7D
strains expressing RING-Hrd1p-GFP, Hrd1p-GFP, hemi-Hrd1p-GFP or C399S-Hrd1p-GFP. Cells were grown to log phase and ob-
served by fluorescence microscopy. Position of the nucleus in each cell was visualized by DAPI staining (data not shown). Arrows indi-
cate the perinuclear, ER localization of the cellular GFP fluorescence, which in all cases is similar to the ER localization of Hmg2p-GFP
(right). (b) COOH-terminal RING-H2 domain of Hrd1p was exposed to the cytosol. Protease protection assay using isolated intact mi-
crosomes from strains expressing either 3HA-RING-Hrd1p, 3HA-Hrd1p, or 3HA-Hrd3p and 1myc-Hmg2p. Microsomes were treated
with the indicated concentrations of trypsin in the absence or presence of Triton X-100 (X). Levels of each protein were assessed by im-
munoblotting using antibodies specific for the fused epitope tags or for the native protein in the case of Kar2p. For each protein ob-
served, total amount in the cell was comparable to that found only in the crude microsomes (compare Lys lane with 0 lane). (c) Protease
protection of untagged Hrd1p. Same experiment as in panel b, using both trypsin (left) or proteinase K (right). Hrd1p was immunoblot-
ted with antisera against the 203 residue COOH-terminal region of Hrd1p. On the left, the black arrow indicates the trypsin-insensitive
fragment of full-length Hrd1p, and the gray arrow indicates the trypsin-insensitive fragment for RING-Hrd1p. For the proteinase K ex-
periment, the blot for 3HA-Hrd1p (second from left) was stripped and reprobed with an anti-HA mAb to detect both 3HA-Hrd1p and
3HA-Hrd3p (far right). (d) Coexpression of RING-Hrd1p and hemi-Hrd1p complemented the hrd1D allele for mevalonate pathway–
regulated Hmg2p-GFP degradation. Cells containing the hrd1D allele and expressing Hmg2p-GFP and either RING-Hrd1p, hemi-
Hrd1p, or both were grown to log phase and analyzed by flow cytometry (left). To assess proper regulation of Hmg2p-GFP degradation,
zaragozic acid (10 mg/ml) or lovastatin (25 mg/ml) was added to cells early in log phase and cells were allowed to grow for 4 h before
flow cytometric analysis (middle and right). (e) Coexpression of RING-Hrd1p and hemi-Hrd1p complemented the hrd1D allele for con-
stitutive 6myc-Hmg2p degradation. Cells containing the hrd1D allele and expressing 6myc-Hmg2p and either RING-Hrd1p, hemi-
Hrd1p, or both were subject to a cycloheximide chase assay. Cell lysates were prepared at the indicated times after cycloheximide addi-
tion and immunoblotted using the 9E10 anti-myc mAb.Gardner et al. Transmembrane Control of Hrd1p by Hrd3p 77
any protease-insensitive bands was seen for 3HA-Hrd1p
(data not shown; see also Fig. 4 c, far right), indicating that
the HA epitope tag was completely destroyed by protease
treatment. Thus, the COOH terminus of full-length Hrd1p
was also present on the cytosolic face of the ER mem-
brane.
To ensure that these results were not caused by the
added epitope sequences, we repeated our experiment us-
ing untagged Hrd1p and polyclonal antisera specific for
residues 348–551 of Hrd1p. Using the polyclonal antisera,
we found that COOH-terminal RING-H2 domain of nor-
mal, untagged, full-length Hrd1p was clearly trypsin sensi-
tive in the absence of any added detergent and was no dif-
ferent from the HA-tagged version of full-length Hrd1p
(Fig. 4 c, left panels). Control proteins Hrd3p, Kar2p and
1myc-Hmg2p showed identical responses to those deter-
mined in Fig. 4 b (data not shown). However, in contrast
to the experiments using the HA mAb for detection, use
of the polyclonal Hrd1p antisera did result in detection of
a 32-kD trypsin-insensitive proteolytic fragment when mi-
crosomes containing either tagged or untagged full-length
Hrd1p were subject to detergent-free trypsin digestion
(Fig. 4 c, black arrow). The isolated, untagged COOH-ter-
minal RING-Hrd1p protein was similarly trypsin sensitive
(Fig. 4 c), also yielding a trypsin-protected proteolytic
fragment that was 16 instead of 32 kD (gray arrow). To re-
solve whether the protease insensitivity of this fragment
from the RING-H2 domains was specific for trypsin or
was instead indicative of a protected lumenal localization,
we repeated these studies using proteinase K. In fact, the
entire COOH-terminal region of either full-length Hrd1p
or the isolated RING-Hrd1p was completely proteinase K
sensitive (.95% digestion) in the absence of detergent
(Fig. 4 c, right panels), with no accumulation of a pro-
tected, immunoreactive fragment. In contrast, the mostly
lumenal 3HA-Hrd3p was insensitive to proteinase K addi-
tion in the absence of detergent (Fig. 4 c, far right), indi-
cating that the microsomes were intact. Thus, the partial
trypsin insensitivity of the Hrd1p COOH-terminal domain
appeared not to be a result of lumenal sequestration, but
rather a structural feature of the COOH-terminal region.
Our protease protection data indicated that the Hrd1p
COOH-terminal RING-H2 domain, whether expressed
alone or as part of Hrd1p, was exposed to the cytosolic
face of the ER membrane. As an independent and strin-
gent test of this idea, we asked if the isolated Hrd1p
COOH-terminal domain could function in ERAD when
expressed with the isolated transmembrane domain. In-
deed, coexpression of hemi-Hrd1p and RING-Hrd1p par-
tially complemented the hrd1D allele for Hmg2p-GFP
degradation, whereas expression of either hemi-Hrd1p or
RING-Hrd1p alone did not (Fig. 4 d, left). Furthermore,
the partially restored Hmg2p-GFP degradation was nor-
mally regulated by inhibitors of the mevalonate pathway,
as seen by the expected effects on cellular Hmg2p-GFP
fluorescence from addition of the degradation-stimulating
zaragozic acid or degradation-slowing lovastatin (Fig. 4 d,
middle and right, ZA and Lov, respectively). Coexpres-
sion of both hemi-Hrd1p and RING-Hrd1p also comple-
mented the hrd1D allele for the constitutive degradation
of misfolded 6myc-Hmg2p as measured directly by cyclo-
heximide chase (Fig. 4 e).
Thus, the COOH-terminal RING-H2 domain of Hrd1p
was localized to the cytosolic side of the ER membrane
when part of full-length Hrd1p or when expressed in isola-
tion as RING-Hrd1p.
Hrd3p Lumenal Determinants Mediated Stabilization of 
Hrd1p and a Separate Function in ERAD
The bulk of the Hrd3p sequence is found in the ER lumen
with a small COOH-terminal region that is located in the
cytosol (Plemper et al., 1999; Saito et al., 1999; and Fig. 4
b). The RING-H2 domain of Hrd1p, which is required for
both ERAD and Hrd1p degradation, is located in the cy-
tosol (Fig. 4, b and c). Since Hrd3p regulates the activity of
Figure 5. Hrd3p was required for ER
degradation, not just Hrd1p stability.
(a) Topology of Hrd3p. The start and
end of each putative domain are
marked with the corresponding amino
acid residue number in the Hrd3p cod-
ing sequence. (b) Hrd1p stability in the
presence of Hrd3p truncation mu-
tants. Stability of 3HA-Hrd1p was as-
sessed by cycloheximide chase assay in
isogenic strains coexpressing 3HA-
Hrd1p and 1myc-Hmg2p with either
the normal HRD3 allele, the hrd3D al-
lele, the HRD31–767 allele, the hrd31–392
allele, or the hrd3357–833 allele. Lysates
were prepared at the indicated times
after cycloheximide addition and im-
munoblotted for the levels of 3HA-
Hrd1p using an anti-HA mAb (top) or
levels of 1myc-Hmg2p using an anti-
myc mAb (bottom). (c) Hmg2p-GFP
degradation in the presence of various
Hrd3p truncation mutants. Strains ex-
pressing Hmg2p-GFP with either the
normal HRD3 allele, the hrd3D allele,
the HRD31–767 allele, the hrd31–392 al-
lele, or the hrd3357–833 allele were ana-
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RING-H2 domain, we examined if this was mediated by
the Hrd3p lumenal domain.
We prepared several truncation mutants of HRD3 in or-
der to examine the role of the Hrd3p lumenal regions in
both Hrd1p stability and ERAD. The domain organiza-
tion of Hrd3p is shown in Fig. 5 a. The Hrd3p sequence in-
cludes an NH2-terminal lumenal domain (residues 1–767)
containing a cleavable NH2-terminal signal sequence and a
region (residues 391–767) with high homology to C. ele-
gans SEL-1 and murine sel-1l (35% identity and 58% simi-
larity) (Hampton et al., 1996a; Grant and Greenwald,
1997; Donoviel et al., 1998), followed by a COOH-termi-
nal transmembrane span and a poorly conserved COOH-
terminal cytosolic domain. We engineered a truncated
HRD3 allele that expressed only the lumenal domain of
Hrd3p from the normal promoter (HRD31–767). When the
resulting lumenal Hrd3p1–767 was expressed from single
copy in hrd3D cells, both Hrd1p stability and ER degrada-
tion of Hmg2p were restored (Fig. 5, b and c). Comple-
mentation of the hrd3D allele by the purely lumenal
Hrd3p1–767 was complete, as observed by the superimpos-
able Hmg2p-GFP cellular fluorescence histograms from
the HRD31–767 cells and normal HRD3 cells (Fig. 5 d).
Thus, the transmembrane and cytosolic regions of Hrd3p
were dispensable for both Hrd3p-mediated stabilization of
Hrd1p and ERAD. Since the critical Hrd1p RING-H2 do-
main is in the cytosol and Hrd3p1–767 is entirely lumenal
(data not shown), the stable transmembrane domain of
Hrd1p must transmit regulatory information across the
ER membrane from lumenal determinants of Hrd3p to
the cytosolic Hrd1p RING-H2 domain.
Although Hrd3p is clearly important for ERAD and
Hrd1p stabilization, the effect of the hrd3D allele can be
suppressed by overexpression of Hrd1p (Plemper et al.,
1999; see Fig. 6 c). This could be interpreted to mean that
the only function of Hrd3p is maintenance of Hrd1p
steady state levels. To address this issue, we have looked
for and discovered an allele of HRD3 that still allows
Hrd1p stability, but does not allow normal ERAD. When
codons 24–356 were excised from HRD3 (so that the sig-
nal sequence was still made), expression of the truncated
Hrd3p, Hrd3p357–833, allowed stabilization of Hrd1p (Fig. 5
b), but did not allow ERAD of 1myc-Hmg2p (Fig. 5 c) or
Hmg2p-GFP (Fig. 5 d). In fact, comparison of the cellu-
lar fluorescence histograms showed that cells expressing
Hrd3p357–833 were equally deficient for ERAD as cells with
the hrd3D allele, despite the restored stability and steady
state levels of Hrd1p. Thus, the NH2-terminal region of
Hrd3p (residues 1–356) appeared to be involved in aspects
of ERAD distinct from Hrd1p stability. Expression of only
the first 390 residues of Hrd3p did not allow Hrd1p stabil-
ity or ERAD. Thus, Hrd1p stabilization required determi-
Figure 6. Regulation of Hrd1p by Hrd3p results in equal stoichiometry. (a) Hrd1p and Hrd3p are expressed at equivalent levels in cells.
Log phase cells coexpressing 3HA-Hrd1p from its native promoter and either 3HA-Hrd3p from its native promoter or the TDH3 pro-
moter (PTDH3HRD3) were lysed and immunoblotted with an anti-HA mAb to determine the levels of 3HA-Hrd1p and 3HA-Hrd3p.
Fractions indicate dilutions of original lysates. Asterisk denotes a proteolytic product of Hrd3p as a result of cell lysis. (b) Effect of
C399S mutation on Hrd1p levels. Strains that coexpressed 3HA-Hrd3p from its native promoter and either 3HA-Hrd1p or 3HA-C399S-
Hrd1p from the native HRD1 promoter were lysed and immunoblotted with an anti-HA mAb as in panel a. (c) Hrd1p overexpression
enhanced Hmg2p-GFP degradation and suppressed the stabilizing effect of the hrd3D allele. Strains expressing Hmg2p-GFP with either
the HRD3 or hrd3D allele and carrying the PTDH3-HRD1 allele were analyzed by flow cytometry. (d) Hrd3p overexpression slightly sta-
bilized both Hmg2p-GFP and 6myc-Hmg2p-GFP. Hmg2p-GFP or 6myc-Hmg2p-GFP steady state levels in otherwise isogenic strains
were determined by flow cytometric analysis, with or without the PTDH3-HRD3 allele.Gardner et al. Transmembrane Control of Hrd1p by Hrd3p 79
nants in the COOH-terminal portion of Hrd3p lumenal
domain (residues 357–783), whereas the NH2-terminal
portion was dispensable for Hrd1p stability. Both regions
were essential for ERAD when Hrd1p was expressed from
its native locus.
Stoichiometry of the Hrd1p/Hrd3p Complex
Hrd3p determines Hrd1p stability and, thus, Hrd1p steady
state levels. The simplest model is that Hrd3p and Hrd1p
form a complex and only Hrd1p molecules so engaged are
stable. We compared the natural steady state levels of
Hrd1p and Hrd3p to estimate the in vivo stoichiometry.
To do this, we used strains coexpressing identically tagged
(triple HA) versions of each protein from single coding re-
gions under the control of their native promoters. In this
way, each protein could be immunoblotted for identical
epitopes using identical conditions and reagents. When
identically tagged versions of Hrd1p and Hrd3p were ex-
pressed from their genomic loci, the resulting steady state
levels of 3HA-Hrd1p and 3HA-Hrd3p were nearly equiva-
lent, as determined by intensity of signal and diminution
by dilution (Fig. 6 a, left). The similarity of Hrd1p and
Hrd3p levels was consistent with the simple model that
Hrd1p was stabilized by formation of a stoichiometric
complex with Hrd3p.
We next examined if the amount of cellular Hrd3p de-
termined the steady state level of Hrd1p through transsta-
bilization. If Hrd1p were only stable when bound to
Hrd3p, then increasing Hrd3p expression would be ex-
pected to result in increased Hrd1p levels by allowing in-
creased stable complexes. Indeed, elevation of Hrd3p lev-
els  z20-fold by expression from the TDH3 promoter
resulted in a 3-fold increase in Hrd1p steady state levels
(Fig. 6 a, compare right with left panel). Clearly Hrd1p
was not increased to the same extent as Hrd3p. However,
by a costabilization model, the maximal possible effect of
elevating Hrd3p would occur when every molecule of Hrd1p
was stable. To evaluate this maximum effect, we compared
the levels of 3HA-Hrd1p to the levels of the identically ex-
pressed, completely stable 3HA-C399S-Hrd1p (Fig. 3b).
Cellular levels of the stable C399S-Hrd1p were approxi-
mately fourfold higher than wild-type Hrd1p levels (Fig. 6
b, compare right with left panel). Furthermore, elevation
of Hrd3p levels had no effect on the steady state level of
C399S-Hrd1p (data not shown). Thus, the effect of Hrd3p
overexpression on Hrd1p levels was close to the maximal
effect caused by the in cis stabilization of every Hrd1p
molecule synthesized.
The cellular level of Hrd1p is demonstrably important in
ERAD. Hrd1p is rate limiting for a variety of substrates,
including Hmg2p and related proteins. Overexpression of
Hrd1p resulted in enhanced degradation of Hmg2p-GFP
(Fig. 6 c). Furthermore, Hrd1p overexpression suppressed
the stabilizing effect of the hrd3D allele for Hmg2p-GFP
degradation (Fig. 6 c), and CPY* degradation (Plemper et
al., 1999). From these observations alone, it would seem
that the sole function of Hrd3p is to ensure sufficient
amounts of Hrd1p. If so, then Hrd3p overexpression, with
the concomitant increase in the rate-limiting Hrd1p, would
be expected to increase the degradation of HRD path-
way substrates. However, the effect of Hrd3p overexpres-
sion on HRD-dependent degradation was more complex.
The degradation of two separate substrates, mevalonate
pathway–regulated Hmg2p-GFP and constitutive 6myc-
Hmg2p-GFP, was slightly decreased (Fig. 6 d), despite the
fact that Hrd1p levels were increased. These results fur-
ther suggested that Hrd3p has separate functions in addi-
tion to simple maintenance of Hrd1p levels, and are con-
sistent with our discovery of a Hrd3p allele that allowed
Hrd1p stabilization, but did not allow ERAD in strains
with normal levels of Hrd1p (Fig. 5).
Discussion
Both Hrd1p and Hrd3p are broadly involved in ER degra-
dation. In this work, we have demonstrated that these two
proteins interact via the NH2-terminal transmembrane re-
gion of Hrd1p. By rigorously evaluating the orientation of
the Hrd1p, we have discovered that the RING-H2 domain
is present and functions in the cytosol. The regions of
Hrd3p required for control of Hrd1p stability and other
aspects of ERAD reside solely in the ER lumen. Thus,
the HRD complex, involving at least Hrd1p and Hrd3p,
functions on both sides of the ER membrane and com-
municates across this barrier through the Hrd1p trans-
membrane domain to coordinate the cytosolic Hrd1p
RING-H2 domain activity with events that occur on sepa-
rate sides of the ER membrane.
Cytosolic Localization of the Hrd1p COOH-terminal 
RING-H2 Domain
To interpret our experiments and understand Hrd1p func-
tion, we evaluated the cellular location and orientation of
the RING-H2 domain in relation to the ER membrane,
both when part of the full-length, native protein and when
expressed as an isolated protein. We have shown by nu-
merous direct biochemical studies that, in either case, the
Hrd1p COOH-terminal domain was exposed to the cyto-
sol. Furthermore, the isolated Hrd1p COOH-terminal do-
main functioned normally in ERAD when expressed in
the cytosol in trans with the isolated NH2-terminal trans-
membrane domain.
Thus, despite the report of a lumenal localization for the
Hrd1p RING-H2 domain (Bordallo et al., 1998), we have
clearly shown that the COOH-terminal RING-H2 domain
of full-length Hrd1p was exposed to the cytosol. The rea-
son why our results directly opposed those reported is not
clear. The previous conclusions were reached by observa-
tion of Hrd1p’s complete resistance to trypsin (Bordallo et
al., 1998). Although we did not observe this, we did find
that the Hrd1p COOH-terminal domain, whether ex-
pressed alone or as part of Hrd1p, was partially resistant to
this protease. Perhaps the intrinsic trypsin insensitivity of
the Hrd1p COOH terminus varies between different
strains, allowing for the observation of complete protec-
tion in some circumstances. However, the Hrd1p COOH-
terminal region was completely proteinase K sensitive in
the same protocol, indicating that the trypsin resistance is
a feature of Hrd1p structure and not lumenal sequestra-
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A Functionally Important Stoichiometric Hrd1p–Hrd3p 
Complex Mediated by the Hrd1p
Transmembrane Domain
Using different biochemical and genetic assays, we have
shown that Hrd1p and Hrd3p physically interacted
through the Hrd1p NH2-terminal transmembrane domain,
which was both necessary and sufficient for complex for-
mation. In the absence of Hrd3p, Hrd1p is subject to
RING-H2 domain–dependent degradation mediated by
the ER-localized Ubc7p (Plemper et al., 1999; and see
above), whereas in the presence of Hrd3p, it is stable and
abundant. The isolated Hrd1p RING-H2 domain similarly
programs its own degradation, but in a manner indepen-
dent of Hrd3p. Thus, the Hrd1p transmembrane domain
allowed Hrd3p-dependent stabilization of the Hrd1p
RING-H2 domain. Since the transmembrane domain itself
was quite stable regardless of Hrd3p presence, it appeared
that the transmembrane domain served as a transducer for
lumenal Hrd3p regulation to control the cytosolic Hrd1p
RING-H2 domain activity.
A model for the Hrd1p–Hrd3p complex required
knowledge of the relative levels of the two proteins. It has
been suggested that levels of Hrd1p and Hrd3p were
highly disparate with Hrd1p in excess (Plemper et al.,
1999), thus favoring a catalytic role for Hrd3p stabilization
of Hrd1p. However, we directly evaluated the relative nat-
ural levels of Hrd1p and Hrd3p using identically tagged
versions of each protein expressed in the same strain from
the native promoters. By our analysis, the relative levels of
Hrd1p and Hrd3p were actually quite similar. Thus, we
propose that Hrd3p forms a stoichiometric complex with
Hrd1p, via the Hrd1p transmembrane domain, allowing
stabilization of Hrd1p and normal ERAD. By this model,
the levels of Hrd1p are contingent on the levels of Hrd3p,
with the maximal amount of Hrd1p occurring when all
Hrd1p molecules are Hrd3p associated. Any residual, un-
bound Hrd1p would be degraded by the unbridled action
of the RING-H2 domain. Indeed, the level of Hrd3p did
influence the amount of Hrd1p in the cell, and this effect
was similar to that observed when every Hrd1p molecule
was stabilized by the in cis C399S mutation.
The Lumenal Functions of Hrd3p
Most of the Hrd3p sequence resides in the lumen of the
ER (Plemper et al., 1999; Saito et al., 1999), yet one of its
critical functions is to limit the degradation of Hrd1p,
which depends on the ubiquitin ligase activity of the cyto-
solic Hrd1p RING-H2 domain. This suggested that Hrd3p
regulation of Hrd1p stability was through lumen to cytosol
signaling mediated by the Hrd1p transmembrane domain.
We directly tested this idea by engineering an allele of
HRD3 that expressed a version of Hrd3p containing only
the signal sequence and the lumenal domain. This version
of Hrd3p completely complemented the stabilizing effect
of the hrd3D allele by restoration of both Hrd1p stability
and ERAD, indicating that purely lumenal determinants
of Hrd3p functioned in this regard.
This regulatory arrangement, in which the Hrd1p hydro-
phobic anchor functions in transmembrane communica-
tion between another molecule and the active RING-H2
domain, has interesting implications. Although the com-
plete role of this signaling process in ERAD is not known,
it could well be part of the communication that must occur
in coupling lumenal substrate scanning to cytosolic sub-
strate tagging and destruction. More generally, there are
other examples of proteins with a RING-H2 domain con-
nected to a transmembrane anchor (Gemmill et al., 1998,
Okumoto et al., 1998; Lorick et al., 1999). If these and
other unknown membrane-associated RING-H2 domains
are regulated in a similar manner as Hrd1p, then the inter-
actions and location of the corresponding anchors will play
a key role in their function and biology.
In parallel studies, we have demonstrated that Hrd1p
functions both in vivo and in vitro as a RING-H2 ubiquitin
ligase (our unpublished results). Thus, Hrd1p and Hrd3p
appear to be part of an ERAD-specific ubiquitin ligase
complex that functions in the detection and targeting of
ERAD substrates. One main function of Hrd3p is to effect
the stabilization of Hrd1p, preventing the RING-H2 do-
main from programming Hrd1p degradation possibly
through autoubiquitination. However, our studies with
truncation alleles of Hrd3p and overexpression of Hrd3p
indicated that Hrd1p stabilization, although clearly impor-
tant for ERAD, was not the only function of Hrd3p. By
our current model, Hrd3p acts to modulate Hrd1p RING-
H2 ubiquitin ligase activity by communication through the
Hrd1p NH2-terminal transmembrane domain. In the ab-
sence of substrate, Hrd3p stabilizes Hrd1p by binding the
Hrd1p transmembrane domain and suppressing the cyto-
solic RING-H2 domain ubiquitin ligase activity. When
substrate is present, Hrd3p senses the requirement for
Hrd1p RING-H2 domain ubiquitin ligase activity, possibly
by directly binding substrate, and signals through the
Hrd1p transmembrane domain to activate Hrd1p function
in a correct temporal and spatial manner, perhaps by coor-
dinating retrotranslocation with Hrd1p RING-H2 ubiq-
uitin ligase activity. From our truncation analysis, it may
be that the sensing function is mediated by determinants
in the NH2-terminal portion of the Hrd3p (1–390),
whereas determinants that regulate the RING-H2 domain
ubiquitin ligase activity and Hrd1p stability lie in the
COOH-terminal portion of the lumenal domain, although
clearly more analysis is required. It is important to note
that Hrd1p overexpression did allow ERAD substrate
degradation in the absence of Hrd3p, suggesting that
Hrd3p was not required for ERAD. However, it is likely
that the elevated levels of Hrd1p under these conditions,
approximately eightfold higher than in wild-type cells
(data not shown), are sufficient to allow lower efficiency
interaction between Hrd1p and ERAD substrates, which
may normally be aided by Hrd3p.
Implications of the Hrd1p–Hrd3p Complex
Hrd3p determines Hrd1p–Hrd3p stoichiometry by con-
trolling Hrd1p degradation as a likely result of Hrd1p au-
toubiquitination. Stabilization as a tactic to ensure correct
stoichiometry is a feature of other complexes such as T cell
receptors, low density lipoproteins, and yeast transcription
factors (Lippincott-Schwartz et al., 1988; Wileman et al.,
1993; Fisher et al., 1997; Zhou et al., 1998). This mecha-
nism may also be involved in self-regulation of ubiquitina-
tion machinery. In several cases, isolated RING-H2 pro-Gardner et al. Transmembrane Control of Hrd1p by Hrd3p 81
teins from known E3 complexes, including Hrd1p, catalyze
their own ubiquitination in vitro (Joazeiro et al., 1999;
Lorick et al. 1999; Skowyra et al., 1999; Fang et al., 2000;
and our unpublished results). Similarly, the F box subunit
of the SCF E3 ligase is susceptible to complex-catalyzed
ubiquitination (Galan and Peter, 1999). Furthermore, it
has recently been demonstrated that the RING-H2 com-
ponent of the SCF E3 complex, ROC1, is degraded in a
proteasome-dependent manner, but is stabilized by associ-
ation with cullins (Ohta et al., 1999b). Thus, it is likely that
self-catalyzed ubiquitination and subsequent degradation
of E3 components is a general mode of self-regulation to
maintain complex stoichiometry. In any event, it is clear
that the HRD gene–encoded ERAD E3 complex is a dy-
namic, self-regulating one, with a separate region of
Hrd1p mediating ubiquitination of self and substrate and
another region mediating Hrd3p-dependent communica-
tion across the ER membrane.
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